Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA)
作者： E. Massarelli , V. A. Miller , N. B. Leighl , P. J. Rosen , K. S. Albain
DOI: 10.1200/JCO.2007.25.18_SUPPL.7627
关键词:
摘要: 7627 Background: AVE0005 (VEGF Trap) is a recombinant fusion molecule of the human VEGF receptor extracellular domains and Fc portion IgG1. Methods: This an open-label, single arm, ...
sci-hub.st 参考文章(0)